BI @ ASCO 2013 <br/>Lung Cancer: Not Just One Disease
BI @ ASCO 2013 <br/>BI to present highly anticipated new Phase III results
BI @ ASCO 2013<br/>New Phase III data for afatinib* and nintedanib*
US FDA Grants Priority Review to Boehringer Ingelheim's Afatinib
Unprecedented progression-free survival benefit with afatinib
Boehringer Ingelheim submits first compound
Lung Cancer Animated Infographic
EGFR Mutation Backgrounder
Afatinib delivers unprecedented first line efficacy
LUX-Lung 3 Results - Prof James Yang
LUX-Lung 7 Clinical Trial Infographic
LUX-Lung 8 Clinical Trial Infographic
1
<p>Following an introduction by Prof Jean-Charles Soria, Prof James
Yang, principal investigator of the LUX-Lung 3 trial, presents the
study's results.</p>
2012-06-01T00:00:00247000802471Webcast: LUX-Lung 3 Trial Results0http://webcast.health-ecomm.com/webcast/Webcast_LUX-Lung_3_Trial_Results/249/index.htm00000
Pivotal study on afatinib
Cancer statistics and incidence rates
Importance of EGFR Mutation Testing
LUX-Lung 3 Results - Prof Thomas Lynch
LUX-Lung 6 and other Afatinib Trials
Targeted Cancer Therapies Backgrounder
Pivotal Phase III Results
AfatinibInterview with Prof Thomas J. Lynch, MD
Direct...
Afatinib
BiomarkersInterview with Prof Thomas J. Lynch, MD
Direct...
Biomarkers
Angiokinase Inhibition and Nintedanib (BIBF 1120) Infographic
ErbB family Blockade and Afatinib Infographic
LUME Lung 2 clinical trial infographic
Lung cancer incidence statics in Europe Infographic
LUX Lung 1 clinical trial fact sheet
LUX Lung 1 Clinical Trial Infographic
LUX Lung 2 clinical cancer trial
LUX Lung 2 Clinical Trial Infographic
LUX-Lung 3 Clinical Trial Layered Infographic
The Changing Face of Cancer Infographic
New Lux-Lung 1 data December 2010
Angiokinase inhibitors in lung cancer
Better lung cancer treatment
Improving outcomes in lung cancer
Personalising cancer care and the future of cancer treatments
Non small cell lung cancer overview
Afatinib lung cancer trial results
Boehringer Ingelheim and DxS sign agreement
Boehringer Ingelheim to commence Lux Lung 3 study
Boehringer Ingelheim to present new data at ASCO 2009
Press release LUME-Lung 1+2 November 2008
Clinical trials data BIBF 1120*
Lux phase 3 BIBW 2992 (afatinib)
Ovarian cancer backgrounder
AGO-OVAR 12/LUME-Ovar 1 Ovarian Cancer Trial Infographic
State of Research in Ovarian Cancer
Characteristics and Symptoms of Ovarian Cancer
Targeted Therapies in Ovarian Cancer
Ovarian Cancer Animated Infographic
Ovarian Cancer Statistics Infographic
LUME-Ovar 1 December 2009
Breast Cancer Backgrounder
LUX-Breast 3 Clinical Trial Infographic
LUX-Breast Clinical Trial Programme Infographic
Breast Cancer Animated Infographic
Lux Breast Cancer Trial August 2011
Breast Cancer Statistics Infographic
Could new cancer targets change the outlook for personalised medicine?
LUX-Breast 1 Initiation September 2010
Head and Neck Cancer Backgrounder
LUX-Head & Neck 1 & 2 Trial Initiation
LUX-Head & Neck 1 Trial Infographic
LUX-Head & Neck 2 Trial Infographic
Head and Neck Cancer Treatments
Head and Neck Cancer Trials
Head and Neck Cancer Infographic
BIBW 2992 cancer treatment data
Rare disease day Boehringer Ingelheim announces initiation of pivotal trial
Boehringer Ingelheim to initiate Phase III study in leukaemia
Volasertib* and Polo-like kinase (Plk) Inhibition Infographic
Volasertib* (compound code BI 6727)
Clinical Trials E-Booklet Chapter 1
Clinical Trials E-Booklet Chapter 2
Clinical Trials E-Booklet Chapter 3
Clinical Trials E-Booklet Chapter 4
Clinical Trials E-Booklet Chapter 5
Clinical Trials E-Booklet Chapter 6
BI in Oncology Backgrounder
BI accesses field of oncology
